News from can-fite biopharma A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

( OTC-BB:OPLI,OTC-PINK:CANFY,TelAviv:CFBI,OTC-QX:CANFY)

Feb 05, 2016, 07:00 ET

Can-Fite to Present at BIO CEO & Investor Conference in New York City on February 8, 2016

 Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs being...

Jan 25, 2016, 07:00 ET

Can-Fite CEO Dr. Pnina Fishman to Chair Scientific Session at the 2016 Purinergic Signaling and Cancer Immunotherapy Conference in Vancouver on January 26, 2016

 Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs being...

Jan 19, 2016, 07:00 ET

U.S. Patent & Trademark Office Issues Notice of Allowance for Can-Fite's Sexual Dysfunction Drug CF602

 Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs being...

Jan 11, 2016, 07:00 ET

Can-Fite Announces 2016 Clinical Milestones for its Pipeline of Drugs in Six Indications

 Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs being...

Jan 08, 2016, 07:00 ET

Can-Fite to Present at Biotech Showcase in San Francisco on January 13, 2016

 Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs being...

Jan 05, 2016, 07:00 ET

Can-Fite Submits Phase III Protocol to IRB for CF101 in the Treatment of Rheumatoid Arthritis

 Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs being...

Dec 17, 2015, 07:00 ET

Can-Fite's CF101 Granted Patent in Japan for Intraocular Pressure a Key Cause of Glaucoma

 Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs being...

Dec 07, 2015, 07:00 ET

Can-Fite Subsidiary, OphthaliX, Announces Completion of Patient Enrollment in Phase II Glaucoma Study for CF101

 Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs being...

Nov 27, 2015, 07:00 ET

Can-Fite Reports Financial Results for Nine Months Ended September 30, 2015

 Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs being...

Nov 23, 2015, 07:00 ET

Can-Fite Announces Compelling Pre-Clinical Data on CF102 in the Treatment of Non-Alcoholic Steatohepatitis (NASH)

 Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address...

Oct 26, 2015, 07:00 ET

Can-Fite to Participate in BIO-Europe Partnering Conference on November 2-5, 2015 in Munich, Germany

 Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that...

Oct 22, 2015, 07:00 ET

New Study Demonstrates CF602 Mechanism of Action to Improve Sexual Dysfunction

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address...

Oct 13, 2015, 08:00 ET

Can-Fite BioPharma Announces $4.8 Million Registered Direct Offering

 Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that...

Oct 12, 2015, 07:00 ET

European Medicines Agency Grants Orphan Designation to Can-Fite's CF102 in the Treatment of Liver Cancer

 Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that...

Oct 07, 2015, 07:00 ET

Can-Fite to Deliver 2 Presentations on its Cancer Drug CF102 at the 20th World Congress on Advances in Oncology and 18th International Symposium on Molecular Medicine on October 8-10, 2015 in Athens

 Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs being...

Sep 29, 2015, 10:11 ET

Can-Fite to Present CF101 Psoriasis Data at Late Breaking Session of the EADV Congress in Copenhagen on October 10, 2015

 Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs being...

Sep 24, 2015, 13:49 ET

Can-Fite BioPharma Closes $9 Million Registered Direct Offering

 Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that...

Sep 19, 2015, 23:56 ET

Can-Fite BioPharma Announces $9 Million Registered Direct Offering

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address...

Sep 17, 2015, 07:00 ET

U.S. Food and Drug Administration Grants Fast Track Designation to Can-Fite's CF102 in the Treatment of Liver Cancer

 Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address...

Sep 01, 2015, 07:00 ET

Can-Fite to Present at Rodman & Renshaw 17th Annual Global Investment Conference on September 9, 2015

 Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that...